**May 22, 2026**

| | |
|---|---|
| To, | To, |
| **BSE Limited** | **National Stock Exchange of India Limited** |
| Listing Compliance & Legal Regulatory | Listing & Compliance |
| Phiroze Jeejeebhoy Towers, | Exchange Plaza, Bandra-Kurla Complex, |
| Dalal Street, Mumbai - 400 001 | Bandra East, Mumbai 400 051 |
| Stock Code: 543233 | Stock Symbol: CHEMCON |

Dear Sir/Madam,

**Sub: Investor Presentation**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing obligations and Disclosure Requirements), Regulations, 2015, please find enclose herewith the "Investor Presentation" for May 2026.

The aforementioned presentation is also being uploaded on the Company's website at www.cscpl.com.

We request you to take the above on your records.

Thanking you,
Yours faithfully,
**For Chemcon Speciality Chemicals Limited**

SHAHILKUMAR M KAPATEL
Digitally signed by SHAHILKUMAR M KAPATEL
Date: 2026.05.22 19:43:23 +05'30'

Shahilkumar Kapatel
Company Secretary & Compliance Officer
Membership No.: A52211

# Chemcon Speciality Chemicals Limited
# Investor Presentation – May 2026

# Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Chemcon Speciality Chemicals Limited (the "Company"),** have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

# Q4 & FY26
# Performance Highlights

# Q4 & FY26 Performance Highlights

*“The company reported revenue of ₹75 crore for Q4FY26, a 37% YoY growth and a healthy improvement in business performance on both a sequential and on year-on-year basis. For the FY26, the Company recorded revenue of ₹240 crore registering a 16% YoY growth. Overall performance during the year were partly affected by subdued demand conditions, pricing pressure across key products, geopolitical uncertainties, and volatility in crude oil prices.*

*During the quarter, both the Organic and Inorganic Chemicals segments delivered improved performance, driven by higher volumes and better realizations across key products. Newer products such as Bromobenzene and 2-Bromo have seen encouraging response from end user industries like pharmaceutical, agrochemical, aromatic chemical, and other end-user industries. Demand recovery across select products, coupled with improved customer engagement and a strengthened product pipeline, supported the overall improvement in quarterly performance.*

*On the strategic front, the acquisition of Shivam Petrochem Industries through a slump sale is progressing well, with integration activities and license transfers nearing completion. The acquired business is expected to begin contributing to revenues in the coming quarters and will further strengthen our presence across bulk drugs, chemical intermediates, solvents, and specialty chemicals. These facilities will manufacture a completely new range of products and are expected to support future growth initiatives.*

*We remain optimistic in our strategy to diversify and broaden our product offerings, while foreseeing healthy growth opportunities going forward.”*

***Mr. Kamal Aggarwal,***

***Chairman & Managing Director***

Organic chemicals refers to HMDS, CMIC, Bromobenzene and 2 Bromo whereas Inorganic chemicals refer to Bromides

# Financial Highlights

**Revenue from Operations (Rs. Cr)**




**EBITDA (Rs. Cr)**




**PAT (Rs. Cr)**




**Geographic-Wise (%)**




**Business-wise (%)**




**Sales Volume (MT)**




Organic chemicals refers to HMDS, CMIC, Bromobenzene and 2 Bromo whereas Inorganic chemicals refer to Bromides

Export data are inclusive of Deemed Exports

# Financial Highlights

### Revenue from Operations (Rs. Cr)




### EBITDA (Rs. Cr)




### PAT (Rs. Cr)




### Geographic-Wise (%)




### Business-wise (%)




### Sales Volume (MT)




Organic chemicals refers to HMDS, CMIC, Bromobenzene and 2 Bromo whereas Inorganic chemicals refer to Bromides

Export data are inclusive of Deemed Exports

# Inorganic Growth – Acquired Shivam Petrochem Industries

***Acquired Shivam Petrochem Industries for INR 36 crore through a slump sale***

## Company Overview

- Manufactures, processes, trades, and distributes bulk drugs, chemical intermediates, solvents, and other chemical products.

## Key Rationale

- To accelerates growth by acquiring a business that strengthens the Company's core product portfolio
- To unlock cost efficiencies, operational improvements & shared resource advantages
- Adds technical know-how, product capabilities, and experienced talent
- Provides access to new markets, customers, and established relationships.

## Key Products

- Trityl Chloride (TTC)1-[(2-Chlorophenyl)(Diphenyl)
- Methyl] 1H-imidazolePara Toluene Sulfonyl Chloride (PTSCL)
- 2-Chlorotrityl Chloride (2CTC)
- Toluenesulfonylmethyl isocyanide (TosMIC)
- 2-AcetylthiopheneThiophene-
- 2-acetyl ChlorideThiophene-
- 2-carboxaldehydePyridine-4-carbaldehyde

## Annual Turnover
(Rs. in Crores)




Through Slump Sale Agreement, the Company acquired the **entire business** undertaking of M/s. Shivam Petrochem Industries (Partnership Firm, a related party) as a going concern for a lump sum consideration of ₹ 36.00 crore.

*Subject to all necessary approvals

# Profit & Loss Statement

| Particulars (Rs. Crs) | Q4 FY26 | Q4 FY25 | *Y-o-Y* | Q3 FY26 | *Q-o-Q* | FY26 | FY25 | *Y-o-Y* |
|---|---|---|---|---|---|---|---|---|
| **Revenue from Operations** | **75.4** | **54.9** | *37%* | **57.3** | *32%* | **240.0** | **207.4** | *16%* |
| Cost of Goods Sold | 52.4 | 34.0 | | 37.8 | | 155.9 | 120.5 | |
| Employee Cost | 5.3 | 5.1 | | 4.8 | | 20.1 | 19.5 | |
| Other Expenses | 8.8 | 10.1 | | 8.0 | | 33.9 | 34.6 | |
| **EBITDA** | **8.9** | **5.8** | *54%* | **6.7** | *34%* | **30.2** | **32.9** | *-8%* |
| ***EBITDA Margin*** | ***11.8%*** | ***10.5%*** | | ***11.6%*** | | ***12.6%*** | ***15.8%*** | |
| Other Income | 4.2 | 3.2 | | 3.6 | | 15.5 | 14.3 | |
| Depreciation | 3.2 | 2.7 | | 2.8 | | 11.6 | 10.5 | |
| **EBIT** | **9.8** | **6.2** | *57%* | **7.5** | *31%* | **34.1** | **36.6** | *-7%* |
| Finance Cost | 1.0 | 0.8 | | 0.7 | | 2.1 | 3.5 | |
| **Profit before Tax** | **8.8** | **5.4** | *63%* | **6.8** | *29%* | **32.0** | **33.1** | *-4%* |
| Tax | 2.4 | 1.5 | | 1.7 | | 8.4 | 8.7 | |
| **PAT** | **6.4** | **3.9** | *61%* | **5.1** | *25%* | **23.6** | **24.5** | *-3%* |
| ***PAT Margin %*** | ***8.4%*** | ***7.2%*** | | ***8.9%*** | | ***9.8%*** | ***11.8%*** | |
| Basic EPS | 1.74 | 1.08 | | 1.39 | | 6.44 | 6.68 | |

# Balance Sheet

| ASSETS (Rs. Crs) | Mar-26 | Mar-25 |
|---|---|---|
| **Non-Current Assets** | | |
| a) Property, Plant And Equipment | 194.6 | 148.7 |
| b) Capital Work in Progress | 20.9 | 39.9 |
| c) Right Of Use Asset | - | - |
| d) Intangible Assets | 0.0 | 0.0 |
| e) Investments | 2.6 | 0.3 |
| f) Other Financial Assets | 1.1 | 42.6 |
| g) Other Non-Current Assets | 2.7 | 3.5 |
| | | |
| **Sub-Total - Non-Current Assets** | **222.0** | **234.9** |
| | | |
| **Current Assets** | | |
| a) Inventories | 67.3 | 86.1 |
| b) Financial Assets | | |
| i) Investments | 7.8 | 9.8 |
| ii) Trade Receivables | 63.5 | 51.7 |
| iii) Cash And Cash Equivalents | 10.4 | 7.1 |
| iv) Bank Balances | 178.2 | 134.4 |
| v) Other Financial Assets | 8.5 | 7.1 |
| c) Other Current Assets | 9.6 | 22.6 |
| d) Current tax assets | 0.6 | 0.2 |
| **Sub-Total - Current Assets** | **346.0** | **319.0** |
| **Total - Assets** | **568.0** | **553.9** |

| EQUITY AND LIABILITIES14 | Mar-26 | Mar-25 |
|---|---|---|
| **EQUITY AND LIABILITIES** | | |
| **Equity** | | |
| a) Equity Share Capital | 36.6 | 36.6 |
| b) Other Equity | 446.5 | 464.0 |
| **Total Equity** | **483.1** | **500.7** |
| **Liabilities** | | |
| **Non-Current Liabilities** | | |
| a) Financial Liabilities | | |
| i) Borrowings | 0.1 | 0.2 |
| ii) Lease Liabilities | - | - |
| iii) Other financial liabilities | - | - |
| b) Non current Provisions | 0.3 | 0.8 |
| c) Deferred Tax Liabilities (Net) | 5.5 | 4.6 |
| d) Other Non-current liabilities | 0.4 | - |
| **Sub-Total - Non-Current Liabilities** | **6.3** | **5.6** |
| **Current Liabilities** | | |
| a) Financial Liabilities | | |
| i) Borrowing | 53.1 | 24.5 |
| ii) Trade Payables | 17.9 | 16.3 |
| iii) Other Financial Liabilities | 3.4 | 4.2 |
| iv) Lease Liabilities | - | - |
| b) Other Current Liabilities | 3.8 | 2.4 |
| c) Short Term Provisions | 0.3 | 0.3 |
| d) Current tax Liabilities | - | - |
| **Sub-Total - Current Liabilities** | **78.5** | **47.7** |
| **Total - Equity And Liabilities** | **568.0** | **553.9** |

# Cash Flow Statement

| Particulars (Rs. Crs.) | Mar-26 | Mar-25 |
| --- | --- | --- |
| **Net Profit Before Tax** | **32.0** | **33.1** |
| Adjustments for: Non Cash Items / Other Investment or Financial Items | -0.1 | 0.4 |
| **Operating profit before working capital changes** | **31.9** | **33.5** |
| Changes in working capital | 17.4 | 7.4 |
| **Cash generated from Operations** | **49.2** | **41.0** |
| Direct taxes paid (net of refund) | -7.7 | -2.6 |
| **Net Cash from Operating Activities** | **41.5** | **38.3** |
| **Net Cash from Investing Activities** | **-35.3** | **-16.7** |
| **Net Cash from Financing Activities** | **-3.0** | **-21.5** |
| **Net Decrease in Cash and Cash equivalents** | **3.3** | **0.1** |
| Add: Cash & Cash equivalents at the beginning of the period | 7.1 | 7.1 |
| **Cash & Cash equivalents at the end of the period** | **10.4** | **7.1** |

# Company Overview

# Company Snapshot

- Incorporated in 1988
- Manufacturer of Speciality Chemicals
- An ISO 9001:2015 and ISO 14001:2015 Certified Company
- Business Verticals: Organic Chemicals and Inorganic Chemicals
- Manufacturing Facilities near Manjusar, Vadodara, Gujarat
- 9 Operational Plants, 6 Owned Warehouses

- **Only Manufacturer** of HMDS in India
- **3rd Largest** Manufacturer of HMDS Worldwide
- **Largest** Manufacturer of CMIC worldwide
- **Only Manufacturer** of Zinc Bromide in India
- **Largest** Manufacturer of Calcium Bromide in India

Organic chemicals refers to HMDS, CMIC, Bromobenzene and 2 Bromo whereas Inorganic chemicals refer to Bromides

# Evolution

### FY89

» Company was incorporated as Gujarat Quinone Private Limited

### FY95-98

» First sale of few chemical products
- Pyridine Hydrobromide
- Para Nitro Benzyl Bromide
- Methyl Iodide
- GA-1

### FY01-03

» Commenced **HMDS** Business in 2001

» Discontinued few products due to lower demand

### FY05

» First export shipment of **HMDS**

» Amalgamation of Chemcon Engineers Private Limited with Gujarat Quinone Private Limited; name changed to "Chemcon Speciality Chemicals Private Limited"

### FY14-16

» First sale of **CMIC**

» First sale of **Calcium Bromide** (Solution)

» First sale of **Zinc Bromide** (Solution)

### FY17

» First sale of **Calcium Bromide** (Powder)

» First sale of **Sodium Bromide** (Solution)

### FY18

» Increase in annual installed production capacity for
- **CMIC** from 600 to 1,200 MTPA;
- **Oilwell Completion** Chemicals from 7,200 to 14,400 MTPA

### FY19

» Increase in annual installed production capacity for CMIC from 1,200 MTPA to 1,800 MTPA

### FY20-21

» **Increase in HMDS Capacity** by commissioning of plant P7

» **Plant P2 commissioned** with a capacity to manufacture ancillary product of HMDS

### FY22–24

» **Increase in CMIC & TMCS** Capacity by commissioning of plant **P8**

» Increase in bromobenzene capacity by commissioning plant P-9

### FY25

» Added new product, **2 Bromo** with a capacity of **600 MTPA**

### FY26

» Acquired **Shivam Petrochem Industries** through slump sale

# Global Market Presence

## Global Presence

**FY26 Export Contribution*:**

**~41%**

## Key Countries

- United States of America
- Italy
- South Korea
- Germany
- People's Republic of China
- Japan
- United Arab Emirates
- Russia
- Spain
- Thailand
- Malaysia

**Over Two Decades of Experience in Chemicals**

- **Manufacturing**
- **Exports**

**Well Equipped to Seize Upcoming Opportunities**

*Export data are inclusive of Deemed Exports

# Key Long-Term Relationships

## Organic Chemicals

HETERO
LAURUS Labs
HONOUR
AUROBINDO
LUPIN
SANJAY CHEMICALS (INDIA) PRIVATE LIMITED
MACLEODS

## Inorganic Chemicals

Water Systems
PT Saint Laurence Trading Sea Co
CC Gran Limited Liability Company

Longstanding Clients → Strong Base → New Product Development → New Customer Reach

- Top 5 customers contribute ~32%
- Top 10 customers contribute ~48%
- Few customers age more than 2 decades with us
- Major customers have been with us for more than 5 years
- Well equipped to retain market presence
- Leading to increase in new product base and reach out to new customers

Organic chemicals refers to HMDS, CMIC, Bromobenzene and 2 Bromo whereas Inorganic chemicals refer to Bromides

# Moving up the Value Chain

| Business | FY15 Revenue Rs 64 Crs | FY26 Revenue Rs 240 Crs |
|---|---|---|
| Organic Chemicals | Rs 46 Crs | Rs 178 Crs |
| Inorganic Chemicals | Rs 13 Crs | Rs 49 Crs |
| Others | Rs 5 Crs | Rs 13 Crs |



Commenced 2-Bromo business in 2025

Commenced Bromobenzene business in 2023

Commenced Bromide business in 2015

Commenced CMIC business in 2014

Commenced HMDS business in 2001

# Key Certifications

## Key Certificates


## R&D

**In-house laboratory to test**

- Raw materials procured
- New Products & Innovation
- Final products testing at the various stages of the manufacturing process
- Well equipped with new instruments & machinery

## Environment

**Complying All Environment Laws**

- The Environment (Protection) Act, 1986
- Water Prevention and Control of Pollution Act
- Air Prevention and Control of Pollution Act, 1981
- We are a zero-discharge company

# Product Overview

# Product Portfolio

## Organic Chemicals

### HMDS

- HMDS, an organosilicon compound, is a reagent and a precursor to bases that are popular in organic synthesis and organometallic chemistry
- HMDS is widely used in the pharmaceutical industry as a silylating agent in the process of manufacture of pharmaceutical drugs of the Penicillin group

.

### CMIC

- CMIC is an antiviral drug intermediate product, which is a key intermediate for anti-AIDS and anti-hepatitis B drug Tenofovir
- The downstream product of CMIC, Tenofovir is a nucleotide antiviral drug developed by Gilead Corporation of the United States.

### Bromobenzene

- Bromobenzene, is a clear, colourless or pale-yellow liquid. It is manufactured through bromination of benzene in presence of iron and has form of heavy, mobile, colorless liquid having a pungent odor.

### 2 Bromo (Di-Bromo Methane)

- Di- Bromo Methane is a colorless liquid primarily used as a solvent and as an intermediate in the production of various industrial chemicals, including those found in perfumes.

## Inorganic Chemicals

### Bromides

- Oilwell Completion Chemicals are used to complete the well and is normally a salty solution made up of chlorides or bromides
- Company manufacture a range of inorganic bromides, namely: Calcium Bromide (solution and powder), Zinc Bromide (solution) & Sodium Bromide (solution and powder)

***Key Products***

***End User Industry***

***Pharmaceuticals & Others*** | ***Pharmaceuticals*** | ***Agrochemicals & Aromatics*** | ***Oil Drilling & Fluids***

***Business Performance (Rs in cr)***







Export data are inclusive of Deemed Exports

# Manufacturing Facilities

| Sr No | Product categories | Key Products | Installed Capacity (MTPA) |
|---|---|---|---|
| 1 | Organic Chemicals | HMDS, CMIC, Bromobenzene, 2 Bromo and other ancillary products | 11,400 |
| 2 | | Proposed P-10 unit | Q1 FY27e |
| 3 | | Proposed P-11 unit | Q1 FY27e |
| 4 | Inorganic Chemicals | Range of Inorganic Bromides | 15,000 |

**Located at Manjusar near Vadodara, Gujarat**

**9 Operational Units**

**2 Proposed Expansion Plant under process**

**In-House R&D Laboratory**

**6 Owned Warehouses**

Organic chemicals refers to HMDS, CMIC, Bromobenzene and 2 Bromo whereas Inorganic chemicals refer to Bromides

# Located at Manjusar near Vadodara, Gujarat

# Growth Drivers

### Capacity Expansion

Successfully commissioned the P10 and P11 units, adding new manufacturing capacity for organic chemicals.

### Import Substitution

Aims to capitalize on the potential growth of Organic Chemicals in India and to substitute imports

### Exploring New Applications

Plan to expand the new products to have diversified product portfolio with diversified client base

### Cost Efficiencies

Improvement in cost efficiencies through process re-engineering, optimized raw material consumption, and benefits arising from economies of scale.

# Way Forward

Moderate Growth in

**Organic Chemicals**

Healthy Growth in

**Inorganic Chemicals**

Exploring Opportunities in

**New Products**

**Leading to Long Term Sustainable Growth**

**New Products, New Clients, New Applications, New Opportunities**

# Financial Highlights

# Financial Trends

**Total Revenue (Rs. Cr)**




**EBITDA (Rs. Cr)**




**PAT (Rs. Cr)**




**Geographic-Wise (%)**




**Business-wise (%)**




**Sales Volume (MT)**




Organic chemicals refers to HMDS, CMIC, Bromobenzene and 2 Bromo whereas Inorganic chemicals refer to Bromides

Export data are inclusive of Deemed Exports

# Thank You

**Chemcon Speciality Chemicals Ltd.**
CIN – L24231GJ1988PLC011652
Mr. Rajesh Gandhi - CFO
Email – rajesh@cscpl.com
www.cscpl.com

**Strategic Growth Advisors Pvt. Ltd.**
CIN - U74140MH2010PTC204285
Mr. Om Kanadia / Ms. Shaily Patwa
Email - om.kanadia@sgapl.net / shaily.p@sgapl.net
+91 8454951156 / +91 9819494608
www.sgapl.net